Last reviewed · How we verify
4SCAR19 and 4SCAR70 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
4SCAR19 and 4SCAR70 (4SCAR19 and 4SCAR70) — Shenzhen Geno-Immune Medical Institute.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 4SCAR19 and 4SCAR70 TARGET | 4SCAR19 and 4SCAR70 | Shenzhen Geno-Immune Medical Institute | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 4SCAR19 and 4SCAR70 CI watch — RSS
- 4SCAR19 and 4SCAR70 CI watch — Atom
- 4SCAR19 and 4SCAR70 CI watch — JSON
- 4SCAR19 and 4SCAR70 alone — RSS
Cite this brief
Drug Landscape (2026). 4SCAR19 and 4SCAR70 — Competitive Intelligence Brief. https://druglandscape.com/ci/4scar19-and-4scar70. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab